The case for & against
Bull & Bear analysis
Bullish
Neuronetics, Inc. (NASDAQ: STIM) is a leading player in the mental health sector, specializing in innovative neuromodulation therapies, particularly through its NeuroStar system for treating major depressive disorder. With the acquisition of Greenbrook TMS, the company has enhanced its clinic operations and is focused on expanding access to mental health treatments across the U.S. amidst increasing competition and evolving patient needs, positioning itself well in the ongoing transformation of mental health care delivery.
Bull says
- ↑84% YoY revenue growth to $32M in Q1 2025 via Greenbrook integration.
- ↑Achieved positive $0.9M operating cash flow in Q4 2025 through cost management.
- ↑On track to roll out Spravato across all eligible clinics by year-end.
- ↑Post-acquisition clinic network boosts access and strengthens market position.
- ↑Compass Pathways psilocybin collaboration may unlock significant new revenues.
- ↑High quality score with positive revisions and strong liquidity support growth.
Bear says
- ↓Negative earnings yield suggests valuation misalignment with growth.
- ↓Operating cash burn of $4–8M and expected $<5M spend raises liquidity concerns.
- ↓Gross margins compressed to 46.9% in Q1 2026 from 49.2% YoY.
- ↓Regulatory probe on billing practices could increase compliance costs.
- ↓Competition and integration execution risk threaten mid-single-digit growth target.
- ↓Weak profitability factors and high short interest reflect market skepticism.
Investment themes with STIM
Health Care Equipment & Supplies↑ +0.40%
Clinical instruments and devices powering patient care
ABT · ISRG · SYK
Most Shorted Stocks↑ +0.54%
Stocks with highest short interest
LITE · FSLY · SPHR
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 08-11-2026neutral
Transcript signals
Read full transcript analysis ›